11.03.17
Emergent BioSolutions
3Q Revenues: $149.4 million (+5%)
3Q Earnings: $33.6 million (+65%)
YTD Revenues: $367.1 million (+9%)
YTD Earnings: $48.7 million (+61%)
Comments: Growth in the quarter was primarily driven by increased product sales, namely Other product sales, and contract manufacturing revenues, offset by lower contracts and grants revenue. Product sales were $114.3 million, up 18% attributable to other product sales and, specifically, sales related to the timing of BAT deliveries to the SNS and RSDL shipments to the DoD, along with international sales of VIGIV and Trobigard, all offset by lower BioThrax sales due to the timing of BioThrax deliveries to the SNS. Contract manufacturing revenue was $18.9 million in the quarter, up 29%, with an increase in fill/finish and bulk manufacturing services.
3Q Revenues: $149.4 million (+5%)
3Q Earnings: $33.6 million (+65%)
YTD Revenues: $367.1 million (+9%)
YTD Earnings: $48.7 million (+61%)
Comments: Growth in the quarter was primarily driven by increased product sales, namely Other product sales, and contract manufacturing revenues, offset by lower contracts and grants revenue. Product sales were $114.3 million, up 18% attributable to other product sales and, specifically, sales related to the timing of BAT deliveries to the SNS and RSDL shipments to the DoD, along with international sales of VIGIV and Trobigard, all offset by lower BioThrax sales due to the timing of BioThrax deliveries to the SNS. Contract manufacturing revenue was $18.9 million in the quarter, up 29%, with an increase in fill/finish and bulk manufacturing services.